Closing the gaps in treatment and management strategies in PAH

Pulmonary arterial hypertension (PAH ) is not typically diagnosed in a timely manner. It is now known that this condition affects all ages and genders and thus should be considered in patients with dyspnea, angina, fatigue, and syncope, particularly if they have other risk factors. There is no cure for PAH, but current approved treatment options that include prostanoids, endothelin-receptor antagonists, and phosphodiesterase type-5 inhibitors can greatly improve a patient's quality of life and may improve survival.

Duke Scholars

Author Richard Andrew Krasuski Medicine, Cardiology